company background image
BLFS logo

BioLife Solutions NasdaqCM:BLFS Stock Report

Last Price

US$26.50

Market Cap

US$1.2b

7D

-1.4%

1Y

59.1%

Updated

24 Dec, 2024

Data

Company Financials +

BioLife Solutions, Inc.

NasdaqCM:BLFS Stock Report

Market Cap: US$1.2b

BLFS Stock Overview

Develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. More details

BLFS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

BioLife Solutions, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for BioLife Solutions
Historical stock prices
Current Share PriceUS$26.50
52 Week HighUS$28.88
52 Week LowUS$14.50
Beta1.92
1 Month Change1.88%
3 Month Change10.51%
1 Year Change59.06%
3 Year Change-33.52%
5 Year Change63.78%
Change since IPO-95.12%

Recent News & Updates

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Shares Climb 27% But Its Business Is Yet to Catch Up

Dec 15
BioLife Solutions, Inc.'s (NASDAQ:BLFS) Shares Climb 27% But Its Business Is Yet to Catch Up

Is It Too Late To Consider Buying BioLife Solutions, Inc. (NASDAQ:BLFS)?

Nov 30
Is It Too Late To Consider Buying BioLife Solutions, Inc. (NASDAQ:BLFS)?

Recent updates

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Shares Climb 27% But Its Business Is Yet to Catch Up

Dec 15
BioLife Solutions, Inc.'s (NASDAQ:BLFS) Shares Climb 27% But Its Business Is Yet to Catch Up

Is It Too Late To Consider Buying BioLife Solutions, Inc. (NASDAQ:BLFS)?

Nov 30
Is It Too Late To Consider Buying BioLife Solutions, Inc. (NASDAQ:BLFS)?

Analysts Have Lowered Expectations For BioLife Solutions, Inc. (NASDAQ:BLFS) After Its Latest Results

Nov 15
Analysts Have Lowered Expectations For BioLife Solutions, Inc. (NASDAQ:BLFS) After Its Latest Results

Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?

Oct 25
Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Sep 14
Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching

Aug 30
Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching

Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%

Aug 14
Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%

BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

Jun 20
BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?

A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)

Jun 05
A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)

Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%

May 14
Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%

Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher

May 13
Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher

Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?

May 11
Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?

Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

Mar 12
Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price

Feb 19
BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price

BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion

Dec 19
BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion

Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term

Aug 17
Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term

Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?

Aug 11
Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?

Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

May 06
Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?

Feb 22
Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?

Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Jan 10
Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?

Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Dec 10
Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?

Shareholder Returns

BLFSUS Life SciencesUS Market
7D-1.4%-0.9%-0.4%
1Y59.1%-5.1%24.8%

Return vs Industry: BLFS exceeded the US Life Sciences industry which returned -5.3% over the past year.

Return vs Market: BLFS exceeded the US Market which returned 23.9% over the past year.

Price Volatility

Is BLFS's price volatile compared to industry and market?
BLFS volatility
BLFS Average Weekly Movement8.1%
Life Sciences Industry Average Movement9.1%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: BLFS has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: BLFS's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987412Rod de Greefwww.biolifesolutions.com

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.

BioLife Solutions, Inc. Fundamentals Summary

How do BioLife Solutions's earnings and revenue compare to its market cap?
BLFS fundamental statistics
Market capUS$1.23b
Earnings (TTM)-US$49.44m
Revenue (TTM)US$146.96m

8.4x

P/S Ratio

-24.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BLFS income statement (TTM)
RevenueUS$146.96m
Cost of RevenueUS$91.81m
Gross ProfitUS$55.15m
Other ExpensesUS$104.59m
Earnings-US$49.44m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.07
Gross Margin37.53%
Net Profit Margin-33.65%
Debt/Equity Ratio6.2%

How did BLFS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 06:13
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioLife Solutions, Inc. is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ashok KumarAegis Capital Corporation
Robert WassermanBenchmark Company
George ZavoicoB. Riley Securities, Inc.